ArticleHeart rhythm O22026
Impact of atrioventricular node ablation and permanent pacing on clinical outcomes, quality of life, and health care utilization in patients with atrial fibrillation.
Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrioventricular node ablation (AVNA) is a class IIa, level B recommendation in the international atrial fibrillation (AF) guidelines. Although its impact on symptoms is known, effects on health care utilization and quality of life (QoL) remain unclear. Conduction system pacing, particularly left bundle branch pacing (LBBP), may further optimize these outcomes. Objective: This study aimed to assess the impact of AVNA on clinical outcomes, QoL, and health care utilization. Methods: Data from patients who underwent AVNA between 2019 and 2024 at a Dutch tertiary referral center were analyzed. Patients received right ventricular pacing, biventricular pacing, or LBBP. Outcomes included (1) clinical outcomes, (2) 36-item Short Form Health Survey QoL scores at baseline and 1-year follow-up, and (3) health care utilization per patient-year 1 year before up to 1 year after AVNA. Results: Of 248 patients (median age 77 years; 44.4% male), most received LBBP (62.5%), followed by biventricular (19.8%) and right ventricular pacing (17.7%). Procedural complications were minimal (0.8%). 90-day mortality was 4.0% (n = 10), 1-year mortality was 10.5% (n = 26), and deaths were related to heart failure (46.2%) or noncardiac causes (53.8%). QoL improved in 67.0% and deteriorated in 14.4%. After AVNA, health care utilization decreased significantly across all domains: outpatient clinic visits (-27.5%), emergency department visits (-72.1%), Holter analyses (-84.2%), electrocardiograms (-52.5%), electrical cardioversions (-98.2%), additional AF ablations (-83.3%), and pacemaker/implantable cardioverter-defibrillator upgrades (-81.8%; all Conclusion: AVNA is a safe intervention associated with a significant reduction in health care utilization and improved QoL. These findings support AVNA as a valuable strategy for managing AF in an increasingly resource-constrained health care environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.